Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A
•Recombinant porcine factor VIII (rpFVIII) is a hemostatic treatment for bleeding in acquired hemophilia A.•The efficacy of rpFVIII can be negatively affected by cross-reacting anti-human FVIII antibodies.•In this cohort, 52% of patients with acquired hemophilia A had baseline cross-reacting antibodies.•Cross-reacting antibodies were associated with decreased FVIII activity levels post-rpFVIII infusion.
Authors
- Carolyne Elbaz (ORCID: https://orcid.org/0000-0003-1572-3984)
- Hina Hanif (ORCID: https://orcid.org/0000-0003-3299-3994)
- Katerina Pavenski
- Jerry Teitel
- Michelle Sholzberg (ORCID: https://orcid.org/0000-0003-1220-0301)
- Maddie Stephen
Institutions
- St. Michael's Hospital (CA)
- University of Toronto (CA)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.rpth.2024.102553
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Sanofi
- Novo Nordisk
- Swedish Orphan Biovitrum